Positive Developments in Outpatient Payment for Barostim
CVRx, Inc. (NASDAQ: CVRX) has recently announced significant progress that positively impacts the payment structure for its breakthrough device, Barostim. This progress was prompted by a new proposal from the Centers for Medicare and Medicaid Services (CMS) aimed at maintaining Barostim implant procedures under the New Technology Ambulatory Payment Classification (APC) 1580. With an expected payment rate of around $45,000 for outpatient procedures, this initiative will likely streamline access for patients undergoing treatment.
Implications of the APC Proposal
The proposed structure by CMS not only provides financial relief but also aligns with the broader objectives of enhancing patient care in the cardiovascular arena. The CMS is actively soliciting feedback on the necessity of a Level 6 Neurostimulator APC, indicating ongoing efforts to refine reimbursement classifications for advanced medical technologies.
Following the recent advancements in reimbursement policies, including the transition of Barostim to a higher-paying MS-DRG for inpatient procedures and its move from Category III to Category I CPT codes effective January 1, 2026, the importance of Barostim in the heart failure treatment spectrum is becoming increasingly clear. These updates validate the clinical efficacy of Barostim and reinforce its potential as a critical component in the care journey for patients.
Insights from CVRx Leadership
Kevin Hykes, the President and CEO of CVRx, expressed gratitude for CMS's proposal, stating, “We appreciate CMS’ proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure.” He further emphasized that these changes, along with favorable proposed payment levels in the recent physician fee schedule, will help in increasing availability of Barostim for patients experiencing heart failure with reduced ejection fraction. This reflects the company's proactive approach towards supporting patient care and encouraging market expansion.
About CVRx
CVRx is committed to enhancing cardiovascular health through innovative medical solutions. As a leader in the neuromodulation field, the company has developed Barostim™, the first medical technology approved by the FDA specifically designed to alleviate symptoms of heart failure. This sophisticated implantable device functions by delivering targeted electrical pulses to baroreceptors in the carotid artery's wall, aiming to restore balance within the autonomic nervous system for better patient outcomes.
Barostim’s Regulatory Milestones
The trajectory of Barostim has been marked by significant regulatory achievements, including its designation as a Breakthrough Device by the FDA and compliance with the EU Medical Device Regulation, earning CE Mark approval for applications in heart failure and resistant hypertension. Such recognition underscores Barostim's potential in transforming lives by addressing severe cardiovascular conditions.
Looking Ahead
As the CMS prepares to finalize the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) rules, expected to be announced later this year, the impact of these changes remains a critical area of focus. These anticipated regulations are set to come into effect on January 1, 2026, marking a new chapter in outpatient cardiovascular care.
With ongoing evaluations and proactive patient management strategies, CVRx is poised for long-term growth and increased adoption of Barostim within the medical community. As such, the company is dedicated to its mission of improving the quality of life for heart failure patients through innovative and effective treatment solutions.
Frequently Asked Questions
What is the Barostim device used for?
The Barostim device is designed to help alleviate symptoms of heart failure by restoring balance to the autonomic nervous system through targeted electrical pulses.
How does the new payment proposal impact CVRx?
The new payment proposal from CMS ensures continued financial support for outpatient Barostim procedures, facilitating access for patients in need of this therapy.
What are the recent advancements regarding Barostim?
Recent advancements include the classification changes that transition Barostim to higher reimbursement tiers and its approval as a Category I CPT code by the end of 2025.
Who is the CEO of CVRx?
Kevin Hykes currently serves as the President and CEO of CVRx, leading the company's efforts in enhancing heart failure treatment solutions.
Is Barostim FDA approved?
Yes, Barostim is FDA-approved for use in heart failure patients, highlighting its clinical efficacy and commitment to patient care in the cardiovascular sector.
